Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
A neo-epitope vaccine paired with pembrolizumab just delivered the first positive randomized trial result in platinum-sensitive ovarian cancer in years. The TEDOVA trial found the combo cut the risk of disease progression by nearly 50% compared to best supportive care. It's a potential breakthrough for patients who've run out of approved maintenance options after PARP inhibitors and bevacizumab.
For patients with platinum-sensitive ovarian cancer (PSOC) who've already been through PARP inhibitors and bevacizumab, the treatment cupboard has been bare — no approved maintenance options, and a string of failed phase 3 trials. The TEDOVA trial just changed that narrative.
The phase 2 trial tested OSE2101 — a neo-epitope vaccine designed to "heat up" immune-cold tumors — combined with pembrolizumab (Keytruda) as maintenance therapy. Presented at the 2026 ASCO Annual Meeting, results showed the combo significantly improved progression-free survival (PFS) vs. best supportive care, cutting progression risk by nearly 50%.
By the Numbers:
Why it matters: This is the first proof-of-concept for a vaccine strategy in ovarian cancer and the first positive randomized trial in the platinum-sensitive setting in roughly five years — offering a potential new maintenance path for a patient population with a notably poor prognosis.
